Integrins mediate cell adhesion and transmit mechanical and chemical signals to the cell
interior. Various mechanisms deregulate integrin signaling in cancer, empowering tumor …

Advances in omics technologies—such as genomics, transcriptomics, proteomics and
metabolomics—have begun to enable personalized medicine at an extraordinarily detailed …

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …

Prostate cancer adeno-to-neuroendocrine lineage transition has emerged as a mechanism
of targeted therapeutic resistance. Identifying the direct molecular drivers and developing …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However,
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …

Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine
prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor …

Comprehensive genomic characterization of prostate cancer has identified recurrent
alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …